Dr. Reddy's Laboratories Launches Chlordiazepoxide Hydrochloride, Clidinium Bromide Capsules, USP in the US Market
1 September 2021 - - Indian pharmaceutical company Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) has launched Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules USP, 5 mg/2.5 mg, a therapeutic equivalent generic version of Librax (chlordiazepoxide hydrochloride and clidinium bromide) approved by the US Food and Drug Administration (USFDA), the company said.

The Librax brand and generic market had US sales of approximately USD 105.9m MAT for the most recent twelve months ending in July 2021 according to IQVIA Health.

Dr. Reddy's Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100.

Dr. Reddy's Laboratories is an integrated pharmaceutical company.

Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include USA, India, Russia and CIS countries, and Europe.


Related Headlines